Pharmaceutical Technology
JANUARY 23, 2023
Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis. development and commercial milestones. development and commercial milestones.
STAT News
NOVEMBER 30, 2022
The Food and Drug Administration on Wednesday ended its emergency authorization for the only remaining Covid-19 antibody therapy cleared for use, saying variants that render it ineffective are now dominant in the United States. have been growing in prevalence. Read the rest…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 9, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.
Pharmaceutical Technology
NOVEMBER 27, 2022
Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.
Pharma Mirror
JANUARY 29, 2022
An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily. Shenzhen) and a local precision medicine research institute.
XTalks
MAY 9, 2024
Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.
Drug Discovery World
MAY 21, 2024
Ben Holland , CTO and Co-Founder of Antiverse discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics.
Expert insights. Personalized for you.
130 
Let's personalize your content